Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 4/2014

01.12.2014 | short review

Melanoma 2014—an update

verfasst von: ao. Univ.-Prof. Dr. Georg Weinlich, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

The incidence of cutaneous melanoma has been increasing worldwide. Although only 5% of all skin cancers are cutaneous melanoma, more than 90% of all skin cancer-related deaths are attributed to this tumour. The prognosis of metastatic melanoma remains poor with conventional chemotherapy, with survival rates between 6 to 9 months. Even combination regimes (polychemotherapy, poly-chemo-immunotherapy) failed to show a significant survival benefit.
In the past 10 years, major efforts and advances have been made in the understanding of the biology of melanoma. These findings led to the development of new therapeutic agents that revolutionized the treatment of advanced melanoma: Immunotherapies that influence the immune checkpoint molecules (CTLA-4, PD1, PDL1) and targeted therapies blocking the MAPK (mitogen-activated protein kinase) signalling pathway (BRAF, MEK). For the first time in the history of melanoma, these drugs demonstrably prolong progression-free survival (PFS) and overall survival (OS). Meanwhile, we are aware of the fact that immune checkpoint inhibitors can induce longterm responses, but only in a low percentage of patients, whereas the new targeted therapies have a quick effect in the majority of patients, but most of them relapse after a certain time, due to acquired or pre-existing resistance. So, the next years will be characterized by efforts to overcome resistance mechanisms and by combining these new drugs.
Literatur
1.
Zurück zum Zitat Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.PubMedCentralPubMedCrossRef Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.PubMedCentralPubMedCrossRef
2.
Zurück zum Zitat Tavares MC, E. Silva MJ, Rinck JA, et al. Number of sites of metastasis (NSM) and progression-free survival (PFS) in patients (PTS) with melanoma treated with ipilimumab (IPI). J Clin Oncol. 2014;32 (suppl; abstr e20048). Tavares MC, E. Silva MJ, Rinck JA, et al. Number of sites of metastasis (NSM) and progression-free survival (PFS) in patients (PTS) with melanoma treated with ipilimumab (IPI). J Clin Oncol. 2014;32 (suppl; abstr e20048).
3.
Zurück zum Zitat Rodriguez JM, de Olza MA, Codes M, et al. Phase II study evaluating ipilimumab as a single agent in the first-line treatment of adult patients (Pts) with metastatic uveal melanoma (MUM): The GEM-1 trial. J Clin Oncol. 2014;32:5 (suppl; abstr 9033).CrossRef Rodriguez JM, de Olza MA, Codes M, et al. Phase II study evaluating ipilimumab as a single agent in the first-line treatment of adult patients (Pts) with metastatic uveal melanoma (MUM): The GEM-1 trial. J Clin Oncol. 2014;32:5 (suppl; abstr 9033).CrossRef
4.
Zurück zum Zitat Kudchadkar RR, Gibney GT, Dorman D, et al. A phase IB study of ipilimumab with peginterferon alfa-2b for patients with unresectable stages IIIB/C/IV melanoma. J Clin Oncol. 2014;32:5 (suppl; abstr 9098).CrossRef Kudchadkar RR, Gibney GT, Dorman D, et al. A phase IB study of ipilimumab with peginterferon alfa-2b for patients with unresectable stages IIIB/C/IV melanoma. J Clin Oncol. 2014;32:5 (suppl; abstr 9098).CrossRef
5.
Zurück zum Zitat Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Ipilimumab versus placebo after complete resection of stage III melanoma: initial efficacy and safety results from the EORTC 18071 phase III trial. J Clin Oncol. 2014;32:5 (suppl; abstr LBA9008).CrossRef Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Ipilimumab versus placebo after complete resection of stage III melanoma: initial efficacy and safety results from the EORTC 18071 phase III trial. J Clin Oncol. 2014;32:5 (suppl; abstr LBA9008).CrossRef
6.
Zurück zum Zitat Ribas A, Hodi FS, Kefford R, et al. Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). J Clin Oncol. 2014;32:5 (suppl; abstr LBA9000^).CrossRef Ribas A, Hodi FS, Kefford R, et al. Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). J Clin Oncol. 2014;32:5 (suppl; abstr LBA9000^).CrossRef
7.
Zurück zum Zitat Hodi FS, Sznol M, Kluger HM, et al. Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial. J Clin Oncol. 2014;32:5 (suppl; abstr 9002).CrossRef Hodi FS, Sznol M, Kluger HM, et al. Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial. J Clin Oncol. 2014;32:5 (suppl; abstr 9002).CrossRef
8.
Zurück zum Zitat Sznol M, Kluger HM, Callahan MK, et al. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). J Clin Oncol. 2014;32:5 (suppl; abstr LBA9003).CrossRef Sznol M, Kluger HM, Callahan MK, et al. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). J Clin Oncol. 2014;32:5 (suppl; abstr LBA9003).CrossRef
9.
Zurück zum Zitat Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–16.PubMedCentralPubMedCrossRef Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–16.PubMedCentralPubMedCrossRef
10.
Zurück zum Zitat Long GV, Stroyakovsky DL, Gogas H, et al. COMBI-d: a randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation-positive cutaneous melanoma. J Clin Oncol. 2014;32:5 (suppl; abstr 9011).CrossRef Long GV, Stroyakovsky DL, Gogas H, et al. COMBI-d: a randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation-positive cutaneous melanoma. J Clin Oncol. 2014;32:5 (suppl; abstr 9011).CrossRef
11.
Zurück zum Zitat Flaherty K, Daud A, Weber JS, et al. Updated overall survival (OS) for BRF113220, a phase 1–2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D + T) in pts with BRAF V600 mutation-positive (+) metastatic melanoma (MM). J Clin Oncol. 2014;32:5 (suppl; abstr 9010).CrossRef Flaherty K, Daud A, Weber JS, et al. Updated overall survival (OS) for BRF113220, a phase 1–2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D + T) in pts with BRAF V600 mutation-positive (+) metastatic melanoma (MM). J Clin Oncol. 2014;32:5 (suppl; abstr 9010).CrossRef
12.
Zurück zum Zitat Ribas A, Gonzalez R, Pavlick A, et al. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol. 2014;15(9):954–65.PubMedCrossRef Ribas A, Gonzalez R, Pavlick A, et al. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol. 2014;15(9):954–65.PubMedCrossRef
13.
Zurück zum Zitat Dummer R, Robert C, Nyakas M, et al. Initial results from a phase I, open-label, dose escalation study of the oral BRAF inhibitor LGX818 in patients with BRAF V600 mutant advanced or metastatic melanoma. J Clin Oncol. 2013;31 (suppl; abstr 9028). Dummer R, Robert C, Nyakas M, et al. Initial results from a phase I, open-label, dose escalation study of the oral BRAF inhibitor LGX818 in patients with BRAF V600 mutant advanced or metastatic melanoma. J Clin Oncol. 2013;31 (suppl; abstr 9028).
14.
Zurück zum Zitat Kefford R, Miller WH, Shao-Weng Tan D, et al. Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in BRAF V600-dependent advanced solid tumors. J Clin Oncol. 2013;31 (suppl; abstr 9029). Kefford R, Miller WH, Shao-Weng Tan D, et al. Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in BRAF V600-dependent advanced solid tumors. J Clin Oncol. 2013;31 (suppl; abstr 9029).
15.
Zurück zum Zitat Larkin J, Ascierto PA, Dréno B, et al. Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma. N Engl J Med. 2014. Sept 29. [Epub ahead of print]. Larkin J, Ascierto PA, Dréno B, et al. Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma. N Engl J Med. 2014. Sept 29. [Epub ahead of print].
16.
Zurück zum Zitat Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. N Engl J Med. 2014. Sept 29. [Epub ahead of print]. Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. N Engl J Med. 2014. Sept 29. [Epub ahead of print].
Metadaten
Titel
Melanoma 2014—an update
verfasst von
ao. Univ.-Prof. Dr. Georg Weinlich, MD
Publikationsdatum
01.12.2014
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2014
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-014-0182-4

Weitere Artikel der Ausgabe 4/2014

memo - Magazine of European Medical Oncology 4/2014 Zur Ausgabe

editorial

Angiogenesis